Merit Financial Group LLC Has $1.03 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Merit Financial Group LLC boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 87.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,629 shares of the biopharmaceutical company's stock after buying an additional 761 shares during the quarter. Merit Financial Group LLC's holdings in Regeneron Pharmaceuticals were worth $1,033,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of REGN. Pinney & Scofield Inc. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $25,000. OFI Invest Asset Management acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $28,000. Rakuten Securities Inc. grew its position in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares during the last quarter. Tompkins Financial Corp acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $32,000. Finally, Avalon Trust Co acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $36,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $493.22 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20. The stock has a market capitalization of $53.25 billion, a P/E ratio of 12.88, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31. The stock has a fifty day moving average of $569.75 and a 200-day moving average of $657.10.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same period last year, the firm posted $9.55 EPS. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% on a year-over-year basis. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.71%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.96%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on REGN shares. Bank of America decreased their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research report on Thursday, April 17th. The Goldman Sachs Group decreased their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Truist Financial decreased their target price on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their target price for the company from $700.00 to $580.00 in a research report on Friday, May 30th. Finally, Citigroup decreased their target price on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a research report on Monday, June 2nd. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $844.48.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.